Levomethadon Molteni

Levomethadone Hydrochloride, the active ingredient in Levomethadon Molteni, is a synthetic opioid presented as an oral dosage form for oral use. It is employed in the management of opioid dependence and in the treatment of chronic pain in adult patients.

GNH USA supplies Levomethadon Molteni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Levomethadon Molteni acts on the opioid system to address dependence and pain conditions.

Opioid dependence: reduces withdrawal symptoms and supports maintenance therapy in individuals with opioid use disorder. Chronic pain: provides analgesia for severe, persistent pain when other treatments are insufficient. Opioid substitution therapy: serves as a long‑acting opioid agonist for patients transitioning from heroin or other opioids.

Levomethadon Molteni may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: feeling of queasiness or urge to vomit. - Drowsiness: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - QT interval prolongation: cardiac electrical disturbance increasing arrhythmia risk. - Severe hypotension: marked drop in blood pressure causing faintness.

When prescribing Levomethadon Molteni, clinicians should consider several safety measures.

Dose titration: adjust gradually under medical supervision to minimize adverse effects. Concurrent CNS depressants: avoid or use with caution due to additive respiratory depression risk. Cardiac monitoring: assess QT interval in patients with cardiac history or electrolyte disturbances. Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed. Renal or hepatic impairment: consider dose reduction and monitor function. Store at ambient temperature: keep in original container, protect from moisture and light.

Levomethadon Molteni can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression and sedation. - MAO inhibitors: may precipitate severe hypotension or serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): can increase levomethadone plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce effectiveness by lowering drug concentrations. - CNS stimulants (e.g., cocaine): can increase cardiovascular strain. - Antidepressants (e.g., SSRIs): may enhance serotonergic effects, requiring observation.